(Q38886929)

7 September 2017

title

Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients (English)

1 reference

multicenter clinical trial

7 September 2017

main subject

0 references

hepatocellular carcinoma

1 reference

Yan Zhao

1

1 reference

7 September 2017

Hailiang Li

2

1 reference

7 September 2017

Wei Bai

3

1 reference

7 September 2017

Jueshi Liu

4

1 reference

7 September 2017

Weifu Lv

5

1 reference

7 September 2017

Sonia Sahu

6

1 reference

7 September 2017

Sheng Guan

7

1 reference

7 September 2017

Xiao Qin

8

1 reference

7 September 2017

Wenhui Wang

9

1 reference

7 September 2017

Weixin Ren

10

1 reference

7 September 2017

Wei Mu

11

1 reference

7 September 2017

Weidong Guo

12

1 reference

7 September 2017

Shanzhi Gu

13

1 reference

7 September 2017

Yilong Ma

14

1 reference

7 September 2017

Zhanxin Yin

15

1 reference

7 September 2017

Wengang Guo

16

1 reference

7 September 2017

Wenjun Wang

17

1 reference

7 September 2017

Yongji Wang

18

1 reference

7 September 2017

Rafael Duran

19

1 reference

7 September 2017

Daiming Fan

20

1 reference

7 September 2017

Zhuoli Zhang

21

1 reference

7 September 2017

Guohong Han

22

1 reference

7 September 2017

language of work or name

English

0 references

publication date

2 April 2016

1 reference

International Journal of Cancer

7 September 2017

published in

1 reference

7 September 2017

volume

139

1 reference

7 September 2017

issue

4

1 reference

7 September 2017

page(s)

928-937

1 reference

Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma

7 September 2017

cites work

1 reference

21 January 2018

Hepatocellular carcinoma

1 reference

Image-guided ablation of primary liver and renal tumours

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2015

1 reference

Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center

21 January 2018

1 reference

Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study

21 January 2018

1 reference

The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies

21 January 2018

1 reference

Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies

21 January 2018

1 reference

High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial

21 January 2018

1 reference

Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results

21 January 2018

1 reference

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

21 January 2018

1 reference

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

21 January 2018

1 reference

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

21 January 2018

1 reference

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.

21 January 2018

1 reference

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

21 January 2018

1 reference

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study

21 January 2018

1 reference

The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma

21 January 2018

1 reference

Targeted therapy of hepatocellular cancer.

21 January 2018

1 reference

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

Systemic therapies in hepatocellular carcinoma: present and future

21 January 2018

1 reference

Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy

21 January 2018

1 reference

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.30124

1 reference

7 September 2017

1 reference